Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.

Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E.

J Am Coll Surg. 2014 Feb;218(2):163-9. doi: 10.1016/j.jamcollsurg.2013.10.025. Epub 2013 Nov 12.

2.

Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected].

Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK.

PLoS One. 2013 Dec 5;8(12):e82620. doi: 10.1371/journal.pone.0082620. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/b2ee22c9-aa14-4c03-861c-b37f1a842bcd.

3.

Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis.

Kwon M, Lee SJ, Wang Y, Rybak Y, Luna A, Reddy S, Adem A, Beaty BT, Condeelis JS, Libutti SK.

Int J Cancer. 2014 Jul 1;135(1):48-60. doi: 10.1002/ijc.28662. Epub 2014 Feb 20.

4.

Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism.

Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Åkerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP.

Nat Genet. 2013 Sep;45(9):1050-4. doi: 10.1038/ng.2695. Epub 2013 Aug 4.

5.

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma.

Hong CW, Libutti SK, Wood BJ.

Curr Oncol. 2013 Jun;20(3):e274-7. doi: 10.3747/co.20.1266.

6.

Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.

Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y.

Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13.

7.

Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.

Yuan Z, Syrkin G, Adem A, Geha R, Pastoriza J, Vrikshajanani C, Smith T, Quinn TJ, Alemu G, Cho H, Barrett CJ, Arap W, Pasqualini R, Libutti SK.

Cancer Gene Ther. 2013 Jan;20(1):46-56. doi: 10.1038/cgt.2012.83. Epub 2012 Nov 16.

8.

von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.

Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.

Surgery. 2012 Dec;152(6):1106-17. doi: 10.1016/j.surg.2012.08.010. Epub 2012 Oct 27.

9.

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK.

Surgery. 2012 Dec;152(6):1068-77. doi: 10.1016/j.surg.2012.08.021. Epub 2012 Oct 24.

10.

Association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1.

Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK, Jensen RT, Marx SJ, Kebebew E.

J Clin Endocrinol Metab. 2013 Jan;98(1):E109-14. doi: 10.1210/jc.2012-2781. Epub 2012 Oct 23.

11.

Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B.

Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS.

J Clin Endocrinol Metab. 2012 Sep;97(9):3025-30. doi: 10.1210/jc.2012-1655. Epub 2012 Jun 26.

12.

Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors.

Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS.

World J Surg. 2012 Jul;36(7):1517-26. doi: 10.1007/s00268-012-1598-9.

13.

Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor.

Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ.

J Clin Endocrinol Metab. 2012 Jun;97(6):1834-41. doi: 10.1210/jc.2011-3030. Epub 2012 Apr 16.

14.

Three-gene molecular diagnostic model for thyroid cancer.

Prasad NB, Kowalski J, Tsai HL, Talbot K, Somervell H, Kouniavsky G, Wang Y, Dackiw AP, Westra WH, Clark DP, Libutti SK, Umbricht CB, Zeiger MA.

Thyroid. 2012 Mar;22(3):275-84. doi: 10.1089/thy.2011.0169. Epub 2012 Jan 26.

15.

Preoperative thyroid ultrasound is indicated in patients undergoing parathyroidectomy for primary hyperparathyroidism.

Arciero CA, Shiue ZS, Gates JD, Peoples GE, Dackiw AP, Tufano RP, Libutti SK, Zeiger MA, Stojadinovic A.

J Cancer. 2012;3:1-6. Epub 2011 Nov 25.

16.

Operative management for recurrent and metastatic adrenocortical carcinoma.

Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I.

J Surg Oncol. 2012 Jun 1;105(7):709-13. doi: 10.1002/jso.23015. Epub 2011 Dec 20.

17.

Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.

Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, Seidel G, Dromi S, Neeman Z, Kolf M, Black CD, Prabhakar R, Libutti SK.

J Vasc Interv Radiol. 2012 Feb;23(2):248-55.e7. doi: 10.1016/j.jvir.2011.10.018. Epub 2011 Dec 16.

18.

Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.

Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.

Surgery. 2011 Dec;150(6):1122-8. doi: 10.1016/j.surg.2011.09.048.

19.

What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism?

Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E.

Ann Surg Oncol. 2012 Jun;19(6):1881-6. doi: 10.1245/s10434-011-2121-5. Epub 2011 Nov 3.

20.

Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.

Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M.

Mol Cancer Res. 2011 Aug;9(8):1126-38. doi: 10.1158/1541-7786.MCR-11-0162. Epub 2011 Jun 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk